Alex Meraz
@nephroguy.bsky.social
📤 672
📥 291
📝 65
Academic Nephrologist in Winnipeg 🇨🇦. Onconeph and Critical care neph FTW!
reposted by
Alex Meraz
NEJM.org
about 1 month ago
In the SNAP trial, cefazolin was noninferior to flucloxacillin or cloxacillin with respect to 90-day mortality in patients with methicillin-susceptible Staphylococcus aureus bacteremia and had fewer nephrotoxic effects. Read the full trial results:
https://nej.md/4vL0M6m
0
18
13
reposted by
Alex Meraz
NEJM.org
about 1 month ago
In adults without diabetes who had chronic kidney disease, the nonsteroidal mineralocorticoid receptor antagonist finerenone led to a slower decrease in the estimate glomerular filtration rate than placebo over 32 months. Full phase 3 FIND-CKD trial results: https://nej.md/4wWOFV4
#ERA26
0
12
6
reposted by
Alex Meraz
Swapnil Hiremath 🍁🇨🇦
about 1 month ago
Unlike COMPASS, TRACK demonstrates rivaroxaban doesn’t have the same CV benefit in CKD
jamanetwork.com/journals/jam...
Simultaneous pubs from
#ERA26
loading . . .
Low-Dose Rivaroxaban and Cardiovascular Events in Advanced Kidney Disease
This randomized clinical trial examines the safety and efficacy of low-dose rivaroxaban in the treatment of patients with advanced chronic kidney disease at high risk for cardiovascular events.
https://jamanetwork.com/journals/jama/fullarticle/2850100
1
15
8
reposted by
Alex Meraz
Swapnil Hiremath 🍁🇨🇦
about 1 month ago
Final GFR results from Atrasentan (ALIGN) in the Lancet Underwhelming to me - the Flozin + Atrasentan looks pretty good OTOH
www.thelancet.com/journals/lan...
Simulpubs from
#ERA26
loading . . .
Atrasentan in patients with IgA nephropathy (ALIGN): final 2·5-year results from a randomised, double-blind, placebo-controlled, phase 3 trial
Atrasentan reduced proteinuria and preserved kidney function after 2·5 years. This effect was present with or without concomitant SGLT2 inhibitor use. Atrasentan was well tolerated.
https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(26)00960-8/abstract
1
9
3
reposted by
Alex Meraz
Swapnil Hiremath 🍁🇨🇦
about 1 month ago
And FIND CKD is live already on NEJM
www.nejm.org/doi/full/10....
#ERA26
loading . . .
Finerenone in Persons with Chronic Kidney Disease without Diabetes | NEJM
In randomized trials, finerenone, a nonsteroidal mineralocorticoid receptor antagonist, improved kidney and cardiovascular outcomes in patients with type 2 diabetes and chronic kidney disease (CKD)...
https://www.nejm.org/doi/full/10.1056/NEJMoa2604625?query=featured_home
2
16
7
Perhaps the most important slide of
#ERA26
about 1 month ago
0
0
0
reposted by
Alex Meraz
Swapnil Hiremath 🍁🇨🇦
about 1 month ago
Another
#ERA26
simulpub Effect of empa/finerenone on BP, yet another splice from CONFIDENCE
www.ahajournals.org/doi/10.1161/...
(If you want a BP effect, use Spiro)
loading . . .
Safety and Synergy of Finerenone and Empagliflozin in Lowering Blood Pressure | Hypertension
BACKGROUND: This secondary analysis of the CONFIDENCE (combination effect of fInerenone and empagliflozin in participants with chronic kidney disease and type 2 diabetes using a UACR endpoint) trial…
https://www.ahajournals.org/doi/10.1161/HYPERTENSIONAHA.126.27036
0
5
2
reposted by
Alex Meraz
American Journal of Kidney Diseases
2 months ago
Cancer Incidence in People With Glomerular Disease: A Population-Level Study
bit.ly/4smBPMv
(OPEN ACCESS)
0
1
1
reposted by
Alex Meraz
American Journal of Kidney Diseases
2 months ago
Hemodiafiltration: A Mini Review
bit.ly/4awrvuf
0
1
1
reposted by
Alex Meraz
Canadian Society of Nephrology
2 months ago
✨ CSN and CKD-N are happy to welcome Dorry Segev from the USA as keynote speaker for this morning’s joint session on Artificial Intelligence 👨🏻🏫
#csnagm
#csnscn
#ai
0
3
2
reposted by
Alex Meraz
Swapnil Hiremath 🍁🇨🇦
2 months ago
The big experiment failed Giving bonuses and penalizing for performance to increase home dialysis and transplant did nothing. An RCT
jamanetwork.com/journals/jam...
in JAMA health forum
0
6
4
The man, the myth, the legend!
add a skeleton here at some point
2 months ago
0
1
0
reposted by
Alex Meraz
Swapnil Hiremath 🍁🇨🇦
2 months ago
The healthcare costs of the forest fires Making the point we *cannot* afford not to plan
#CSNAGM
1
2
2
Wanna reduce burnout? Less mandatory courses and more AI!
#csnagm
#csnscn
2 months ago
0
3
2
Don’t let previous abnormal surgeries to be a barrier for PD catheter insertion. But, the presence of adhesions has been associated with worse outcomes
#csnagm
#csnscn
2 months ago
1
6
4
Player to has entered: CRB2 the second podocyte autoantigen.
#csnagm
#csnscn
2 months ago
0
2
1
reposted by
Alex Meraz
Canadian Society of Nephrology
2 months ago
📢✨Join us today for the opening session of the 2026 CSN-AGM! Welcome to all attendees in Quebec City & to those following us online from afar! 👋
#csnagm
#csnscn
1
2
3
reposted by
Alex Meraz
American Journal of Kidney Diseases
8 months ago
#RenalPath
: Diffuse granular capillary wall staining for phospholipase A2 receptor (PLA2R). PLA2R staining is positive in approximately 70% of patients with clinically idiopathic membranous nephropathy (immunofluorescence microscopy, PLA2R).
bit.ly/2xVkJzs
(FREE)
0
3
1
Heard that Twitter is imploding. Good riddance
8 months ago
0
0
0
@hswapnil.medsky.social
@kidneyboy.bsky.social
What’s the name of the nephrology song you play at the end of the podcast?
8 months ago
1
0
0
reposted by
Alex Meraz
Swapnil Hiremath 🍁🇨🇦
8 months ago
The second sibeprenlimab paper in
@nejm.org
(At least we gave it an oral at
#KidneyWk
unlike the poster for the phase 2 data in 2023!)
www.nejm.org/doi/full/10....
loading . . .
Sibeprenlimab in IgA Nephropathy — Interim Analysis of a Phase 3 Trial | NEJM
The cytokine A proliferation-inducing ligand (APRIL) is considered a key driver of the pathogenesis of IgA nephropathy. Sibeprenlimab, a humanized IgG2 monoclonal antibody, selectively binds to and...
https://www.nejm.org/doi/full/10.1056/NEJMoa2512133?query=RP&ssotoken=U2FsdGVkX18HwtSgXglJ1gbcCroISBKK7yPln43pSCZV8yPfQWUatNAzAHDZBaHCcgLB1ey0WaqsHwg9PzlzebfiBSX0qqNhK5vqLkva1kwLqzfHXq6r3A1Q2ZJqPOKnmHuZ7VTxPnkrt%2FDjX5BImxr3NHKvBalst0pzallnX5zWjaTtwNLPxgJ7wITboUre4GGzki3ZPnqTE%2BULAIOe5mWs5ItpHCKC8AWsoKuDhtE%3D&cid=NEJM%20Recently%20Published,%20November%208,%202025%20DM2425300_NEJM_Non_Subscriber&bid=-1078256474
1
12
5
reposted by
Alex Meraz
Swapnil Hiremath 🍁🇨🇦
10 months ago
And it’s live Iptacopan in C3GN makes it to
@thelancet.com
www.thelancet.com/journals/lan...
#NephSky
add a skeleton here at some point
1
23
11
reposted by
Alex Meraz
Joel Topf
about 1 year ago
Amazing to me that a seemingly acute event is either A) has long-term sequellae despite being apparently resolving or B) a dramatic and early presentation of profound endothelial disease
add a skeleton here at some point
0
8
5
reposted by
Alex Meraz
Swapnil Hiremath 🍁🇨🇦
about 1 year ago
Way scarier story. Stories.
www.nytimes.com/2025/06/13/t...
(Gift link)
add a skeleton here at some point
0
6
3
reposted by
Alex Meraz
Hugo Diniz, MD 🇵🇹🇪🇺
about 1 year ago
Sibeprenlimab in IgA Nephropathy
#ERA25
* Data presented is the 9-month reduction in proteinuria
0
3
1
Dr Meghan Sise presenting on serum cr/cystatin outcomes in patients treated with cisplatin or carboplatin
#Onconeph
#ERA25
about 1 year ago
0
2
0
reposted by
Alex Meraz
Swapnil Hiremath 🍁🇨🇦
about 1 year ago
Hyperkalemia rates not lower with adding a flozin to the MRA 🤔
www.nejm.org/doi/full/10....
#ERA25
2
11
3
reposted by
Alex Meraz
Swapnil Hiremath 🍁🇨🇦
about 1 year ago
The first
#ERA25
simultaneous pub CONFIDENCE trial of empagliflozin + finerenone in N = 579 Greater reduction in ACR and BP Note the impressive GFR dip
www.nejm.org/doi/full/10....
3
40
23
reposted by
Alex Meraz
NEJM.org
about 1 year ago
In the CONFIDENCE trial in persons with chronic kidney disease and type 2 diabetes, combination therapy with finerenone and empagliflozin led to a greater reduction in the urinary albumin-to-creatinine ratio than either drug alone. Full trial results:
nej.md/4jEVbbk
#ERA25
#MedSky
#Nephrology
1
29
16
@kevinyau.bsky.social
GLP1 agonist master Jedi presenting at
#ERA25
. 💉GLP1 agonist reduce ED visits and hospitalizations!!! 📉Awesome methods. Best of the session: 💊DDP4 for comparison, IPTW, ICES data. Ticking all the right boxes (EPI nerd). 💊Only 40% on SGLT2i!!! We should flozinate more!!!
about 1 year ago
3
9
4
#ERA25
baby!!!
about 1 year ago
1
3
0
reposted by
Alex Meraz
Swapnil Hiremath 🍁🇨🇦
about 1 year ago
Experiential Evidence of Systemic Racism for Indigenous Peoples Navigating Transplantation in Canada - in
@kireports.bsky.social
www.kireports.org/article/S246...
#NephSky
0
7
4
reposted by
Alex Meraz
Swapnil Hiremath 🍁🇨🇦
about 1 year ago
The US spends billions of dollars on binders every year We are doing the RCT to get you the answer - more than 3000 enrolled
ajkdblog.org/2021/06/16/c...
and
www.nephjc.com/news/2021/2/...
loading . . .
Could High Be Better Than Low? Targeting Phosphate in Trials
Phosphate is bad, right? As kidney function declines, phosphate excretion goes down. Serum phosphate levels rise, causing parathyroid hormone (PTH) to increase and bring phosphate down. Phosphate h…
https://ajkdblog.org/2021/06/16/could-high-be-better-than-low-targeting-phosphate-in-trials/
1
6
2
reposted by
Alex Meraz
ASN Publications
over 1 year ago
Torsemide is proposed to have clinically important pharmacokinetic and pharmacodynamic advantages over furosemide. This study found no meaningful pharmacokinetic/pharmacodynamic advantages for torsemide versus furosemide.
bit.ly/JASN0481
1
26
11
reposted by
Alex Meraz
Renal Failure
over 1 year ago
Dapagliflozin improves diabetic kidney disease by inhibiting ferroptosis through β-hydroxybutyrate production
#Nephrology
#endocrinology
#Diabetes
#SGLT2i
#NephSky
www.tandfonline.com/doi/full/10....
loading . . .
Dapagliflozin improves diabetic kidney disease by inhibiting ferroptosis through β-hydroxybutyrate production
Diabetic kidney disease (DKD) is the leading cause of end-stage renal disease. Sodium-glucose cotransporter protein 2 inhibitors (SGLT2i) are antihyperglycemic agents that provide additional renal-...
https://www.tandfonline.com/doi/full/10.1080/0886022X.2024.2438857
0
11
3
reposted by
Alex Meraz
Kidney Medicine Journal
over 1 year ago
Case report: Daratumumab for Bortezomib-Refractory Proliferative Glomerulonephritis With Monoclonal Immunoglobulin Deposits in Kidney Allograft: A Case Report
https://buff.ly/3P5dsSc
0
14
6
Feliz Navidad!
over 1 year ago
0
2
0
reposted by
Alex Meraz
Ryan Town
over 1 year ago
💡 Kidney stone patients not meeting their fluid intake goals? Try this one weird trick! Sprinkle a little Carolina reaper powder on their food a couple times a day and 💦🆙 they'll be drinking so much water you'll be looking up the latest
#NephJC
on hyponatremia correction rates! GI docs hate him!
1
6
2
reposted by
Alex Meraz
American Journal of Kidney Diseases
over 1 year ago
Cumulative Blood Pressure Load and Incident CKD
https://bit.ly/4eEtmx7
#OpenAccess
#VisualAbstract
1
2
1
reposted by
Alex Meraz
Jeff Perl
over 1 year ago
Nope we use the patients usual dwell volume
0
5
1
Is there any preferred dwell volume for IP antibiotics?
@pd-perls.bsky.social
#askrenal
#nephsky
over 1 year ago
2
3
4
reposted by
Alex Meraz
Brendon Neuen
over 1 year ago
Prevent kidney failure to reduce carbon emissions ♻️ 🍃 🏭 Our new analysis of CREDENCE assessing environmental impacts from ⬇️ hospitalisations & dialysis 🏥 with SGLT2i SGLT2i ⬇️ greenhouse gas emissions from inpatient bed days & dialysis by 20% (39 kg CO2e per yr)
www.thelancet.com/journals/lan...
0
12
7
Kidney biopsy on aspirin, nay or yay? I am interested in your type 1, blink of an eye, kind of reasoning. Is Dr Glassock yet in Blue Sky?
#askrenal
#nephsky
@kidneyboy.bsky.social
over 1 year ago
6
5
3
Deleting X account today.
#bluesky
all the way
over 1 year ago
0
3
0
reposted by
Alex Meraz
Ron Filipkowski
over 1 year ago
23 million
1172
52296
5145
reposted by
Alex Meraz
UKidney
over 1 year ago
Reposting (fixed link): Check out our new and improved KFRE calculator with a nice visualization of kidney risk plotted on a KDIGO heatmap. For easy reference, go to
ukidney.com/kfre
✨ New features: • Interactive KDIGO heatmap • Clear risk visualization
loading . . .
https://ukidney.com/kfre📊
0
5
3
reposted by
Alex Meraz
UKidney
over 1 year ago
Ever need help converting between different steroid doses or different immunosuppressive agents in transplant? • Envarsus to Cyclosporine IV? • Astagraf/Advagraf to Envarsus? • Prednisone to Solucortef? • And many more? We have you covered!
ukid.io/drugs
0
6
3
#nephsky
add a skeleton here at some point
over 1 year ago
0
1
0
reposted by
Alex Meraz
John Scalzi
over 1 year ago
Others have noted it but I will too: The big reason Bluesky is so hot right now is that the people who add value to social media - the frequent posters in specific fields - are here now, talking to each other and creating the "spectator value" that draws users and attention.
loading . . .
Twitter’s heir apparent isn’t X or Threads — it’s Bluesky
The blue bird is dead. Long live the blue sky.
https://www.theverge.com/2024/11/23/24303502/bluesky-next-twitter-threads-x
914
54973
7378
Load more
feeds!
log in